Your browser doesn't support javascript.

Portal Regional da BVS

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

[Clinical and endoscopic efficacy of vedolizumab in patients with ulcerative colitis].

Wiad Lek; 71(2 pt 1): 346-349, 2018.
Artigo em Ucraniano | MEDLINE | ID: mdl-29729171

OBJECTIVE:

Introduction: Ulcerative colitis (UC) is a chronic recurrent idiopathic inflammatory bowel disease that is characterized by a continuous or wave-like course with multifactorial etiopathogenesis. In recent decades, the number of patients with this pathology has been steadily increasing. Therefore, timely detection of UC at the diagnostic stage for the further qualified assistance providing is one of the most important tasks in modern gastroenterology. In recent years, a new group of drugs that can be an alternative to the surgical method of treatment has appeared. These are biological drugs, one of which is vedolizumab.

THE AIM:

to study the changes in clinical and endoscopic parameters in patients with ulcerative colitis, in response to the biological therapy with vedolizumab.

PATIENTS AND METHODS:

Materials and methods: 38 patients with ulcerative colitis were included in this study that lasted 52 weeks. 15 patients of the control group received standard therapy with 5-aminosalicylic acid (5-ASA). 23 patients in the study group received the vedolizumab infusions.

RESULTS:

Results: Clinical response was observed in 16 (69.6%) and 23 (100.0%) patients of the study group at the 6th and 52nd weeks respectively. In control group the clinical response was present in 5 (33.3%) and 9 (60,0%) patients at the 6th and 52nd weeks respectively. Mucosal healing at the 52nd week was observed in 22 (95.7%) patients in the study group and 7 (46.7%) patients in the control group.

CONCLUSION:

Conclusions: Patients who were treated with vedolizumab experienced significant improvement in clinical and endoscopic parameters 52 weeks after treatment initiation compared to the control group.